> top > docs > PubMed:35445052 > annotations

PubMed:35445052 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-162 Sentence denotes Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome:
T2 163-205 Sentence denotes Protocol of a Randomized Controlled Trial.
T3 206-217 Sentence denotes Background:
T4 218-380 Sentence denotes Patients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS).
T5 381-491 Sentence denotes CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality.
T6 492-589 Sentence denotes This study aims to examine the efficacy and safety of roxadustat in the treatment of type 4 CRAS.
T7 590-609 Sentence denotes Methods and Design:
T8 610-679 Sentence denotes This study is designed as a randomized, open-label, controlled trial.
T9 680-813 Sentence denotes A total of 68 patients diagnosed with type 4 CRAS will be randomly divided into roxadustat group and erythropoietin with a 1:1 ratio.
T10 814-1106 Sentence denotes Participants in the roxadustat group will receive roxadustat with an initial dose of 70 or 100 mg three times a week, and participants in the erythropoietin group will receive subcutaneous injection of erythropoietin for 24 weeks, to maintain a hemoglobin ranging from 100 to 120 g per liter.
T11 1107-1273 Sentence denotes The primary outcome is the change in heart function, including brain natriuretic peptide (BNP), 6-min walk test (6-WT), and left ventricular ejection fraction (LVEF).
T12 1274-1711 Sentence denotes Secondary outcomes to be assessed include death, cardiovascular events, hospitalization regarding heart failure, Minnesota Heart Failure Quality of life scale (MLHFQ) score, New York Heart Association (NYHA) cardiac function grade, echocardiographic parameters including left ventricular diastolic diameter and volume (LVDD and LVDV) and ventricular mass (LVM), anemia related parameters, inflammatory parameters, and safety assessments.
T13 1712-1723 Sentence denotes Conclusion:
T14 1724-1817 Sentence denotes The findings of this study will provide potential evidence for roxadustat in CRAS management.
T15 1818-1837 Sentence denotes Trial Registration:
T16 1838-1874 Sentence denotes Chinese Clinical Trial Registry, ID:
T17 1875-1892 Sentence denotes ChiCTR2100050031.
T18 1893-1922 Sentence denotes Registered on 16 August 2021.
T1 0-162 Sentence denotes Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome:
T2 163-205 Sentence denotes Protocol of a Randomized Controlled Trial.
T3 206-217 Sentence denotes Background:
T4 218-380 Sentence denotes Patients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS).
T5 381-491 Sentence denotes CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality.
T6 492-589 Sentence denotes This study aims to examine the efficacy and safety of roxadustat in the treatment of type 4 CRAS.
T7 590-609 Sentence denotes Methods and Design:
T8 610-679 Sentence denotes This study is designed as a randomized, open-label, controlled trial.
T9 680-813 Sentence denotes A total of 68 patients diagnosed with type 4 CRAS will be randomly divided into roxadustat group and erythropoietin with a 1:1 ratio.
T10 814-1106 Sentence denotes Participants in the roxadustat group will receive roxadustat with an initial dose of 70 or 100 mg three times a week, and participants in the erythropoietin group will receive subcutaneous injection of erythropoietin for 24 weeks, to maintain a hemoglobin ranging from 100 to 120 g per liter.
T11 1107-1273 Sentence denotes The primary outcome is the change in heart function, including brain natriuretic peptide (BNP), 6-min walk test (6-WT), and left ventricular ejection fraction (LVEF).
T12 1274-1711 Sentence denotes Secondary outcomes to be assessed include death, cardiovascular events, hospitalization regarding heart failure, Minnesota Heart Failure Quality of life scale (MLHFQ) score, New York Heart Association (NYHA) cardiac function grade, echocardiographic parameters including left ventricular diastolic diameter and volume (LVDD and LVDV) and ventricular mass (LVM), anemia related parameters, inflammatory parameters, and safety assessments.
T13 1712-1723 Sentence denotes Conclusion:
T14 1724-1817 Sentence denotes The findings of this study will provide potential evidence for roxadustat in CRAS management.
T15 1818-1837 Sentence denotes Trial Registration:
T16 1838-1874 Sentence denotes Chinese Clinical Trial Registry, ID:
T17 1875-1892 Sentence denotes ChiCTR2100050031.
T18 1893-1922 Sentence denotes Registered on 16 August 2021.

yaoziqian_800_3

Id Subject Object Predicate Lexical cue
T1 96-106 CI denotes Roxadustat
T10 760-770 CI denotes roxadustat
T11 834-844 CI denotes roxadustat
T12 864-874 CI denotes roxadustat
T13 1787-1797 CI denotes roxadustat
T2 127-161 DP denotes Type 4 Cardiorenal-Anemia Syndrome
T3 338-372 DP denotes type 4 cardiorenal-anemia syndrome
T4 374-378 DP denotes CRAS
T5 381-385 DP denotes CRAS
T8 1801-1805 DP denotes CRAS
T9 546-556 CI denotes roxadustat
T14 718-729 DP denotes type 4 CRAS
T15 577-588 DP denotes type 4 CRAS
T16 781-795 CI denotes erythropoietin
T17 956-970 CI denotes erythropoietin
T18 1016-1030 CI denotes erythropoietin

Zierdiyeerkenaili_800_3

Id Subject Object Predicate Lexical cue
T1 96-106 CI denotes Roxadustat
T10 718-729 DP denotes type 4 CRAS
T11 577-588 DP denotes type 4 CRAS
T12 127-161 DP denotes Type 4 Cardiorenal-Anemia Syndrome
T2 864-874 CI denotes roxadustat
T3 546-556 CI denotes roxadustat
T4 760-770 CI denotes roxadustat
T5 834-844 CI denotes roxadustat
T6 1787-1797 CI denotes roxadustat
T7 1016-1030 CI denotes erythropoietin
T8 781-795 CI denotes erythropoietin
T9 956-970 CI denotes erythropoietin
T13 338-372 DP denotes type 4 cardiorenal-anemia syndrome
T14 374-378 DP denotes CRAS
T15 381-385 DP denotes CRAS
T18 1801-1805 DP denotes CRAS